Key result
ICDs lack clear survival benefit in Duchenne cardiomyopathy because arrhythmic sudden death is rare.
Why the study?
Indications for ICD placement to prevent sudden death in patients with Duchenne cardiomyopathy are not well defined, as recommendations are traditionally extrapolated from adult heart failure guidelines despite sudden arrhythmic death appearing rare in this population.
Does implantable cardioverter-defibrillator (ICD) placement prevent sudden death and prolong life in patients with Duchenne cardiomyopathy?
Does implantable cardioverter-defibrillator (ICD) placement prevent sudden death and prolong life in patients with Duchenne cardiomyopathy?
Routine ICD placement in Duchenne cardiomyopathy lacks strong evidence for prolonging life and should not be strictly extrapolated from adult heart failure guidelines, but rather individualized to patient goals.
Answers are grounded in this paper and cite their sources.
Lacks support for routine ICD use in Duchenne cardiomyopathy; leaves open the need for prospective arrhythmic risk studies.
Dystrophin-deficiency results in a cardiomyopathy of variable onset and deficiency. Myocardial scarring commonly results in cardiac dysfunction, with both atrial and ventricular dysrhythmias. Heart failure, rather than arrhythmia burden, remains the strongest cardiac predictor of mortality in this patient population. Current data suggests the overall rate of sudden cardiac death in pediatric dilated cardiomyopathy is significantly lower than adults. Specifically in the Duchenne cardiomyopathy population, sudden death from an arrhythmic cause appears to be rare, even in patients with previously diagnosed arrhythmias. Despite this, recommendations for implantable cardioverter-defibrillator (ICD) placement in patients with Duchenne cardiomyopathy has traditionally been extrapolated from adult heart failure recommendations based on decreased left-ventricular ejection fraction less than 35%. Early involvement of the cardiologist in the care for patients with dystrophin-deficient cardiomyopathy is recommended for this reason. The indications for ICD placement to prevent sudden death in patients with Duchenne cardiomyopathy are not well defined. There is little evidence to suggest placement meaningfully prolongs life in this population, and should be carefully considered in accordance with the care goals of the patient and his family.
No takes yet. Share an insight, caveat, or question.
Bennett et al. (2020) conducted a review in Duchenne muscular dystrophy with cardiomyopathy. Implantable cardioverter-defibrillator (ICD) placement was evaluated. Implantable cardioverter-defibrillator placement in Duchenne cardiomyopathy lacks clear indications and evidence for prolonging life, as sudden death from arrhythmic causes appears to be rare.
Synapse has enriched 10 related papers. Consider them for comparative context: